Related Experiment Video
Updated: May 15, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilar monoclonal antibodies: a science-based regulatory challenge
Expert Opinion on Biological Therapy
|January 5, 2013
Summary
Developing biosimilar monoclonal antibodies (mAbs) is challenging due to their complexity and species specificity, requiring extensive in vitro and clinical studies. Currently, no biosimilar mAbs are approved, potentially limiting their future use.
Area of Science:
- Biopharmaceutical development
- Immunology
- Regulatory science
Background:
- Monoclonal antibodies (mAbs) are complex biotherapeutics with multi-domain mechanisms of action.
- Regulatory approval for mAb biosimilars requires rigorous, science-based guidelines.
- Extensive comparative in vitro characterization is essential to assess biosimilarity across functional domains.
Discussion:
- The species specificity of mAbs limits the reliability of non-clinical in vivo evaluations.
- Well-designed clinical studies are critical for confirming biosimilarity.
- High development costs associated with biosimilar mAbs are a significant consideration.
Key Insights:
- No biosimilar monoclonal antibodies have received regulatory approval to date.
- The complexity and specific requirements for biosimilar mAb evaluation present substantial hurdles.
- In vitro characterization and clinical trials are paramount for demonstrating biosimilarity.
Outlook:
- The high development costs may lead to the adoption of alternative antibody formats.
- Next-generation antibody therapeutics could supersede the development of current biosimilar mAbs.
- Future biotherapeutic strategies may focus on novel antibody engineering approaches.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...